Enkhtsetseg Purev

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

Jeremy S. Abramson, M. Lia Palomba, Leo I. Gordon et al. · The Lancet · 2020 · 2.2K citations

Hematological Malignancy, Lymphoid Neoplasia, Oncology +5

Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia

Daniel A. Pollyea, Brett M. Stevens, Courtney L. Jones et al. · Nature Medicine · 2018 · 768 citations · Full text

Hematological Malignancy, Medicine, Acute Myeloid Leukemia +9

Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology

Jerald P. Radich, Michael W. Deininger, Camille N. Abboud et al. · Journal of the National Comprehensive Cancer Network · 2018 · 281 citations · Full text

Hematological Malignancy, Chronic Myeloid Leukemia, Medicine +14

Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL.

Jeremy S. Abramson, Leo I. Gordon, Maria Lia Palomba et al. · Journal of Clinical Oncology · 2018 · 166 citations

Drug Safety, Pivotal Trial, Engineering +14

Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001

Jeremy S. Abramson, M. Lia Palomba, Leo I. Gordon et al. · Blood · 2023 · 144 citations · Full text